Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: Beyond bleeding complications

Polskie Archiwum Medycyny Wewnetrznej

Volumn 126, Issue 7-8, 2016, Pages 552-561

  Raschi, Emanuel ^a   Bianchin, Matteo ^a   Ageno, Walter ^b   De Ponti, Roberto ^b   De Ponti, Fabrizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Anticoagulants; Coronary risk; Liver injury; Renal injury; Safety

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; CREATINE KINASE MB; DABIGATRAN; IDRAPARINUX; RIVAROXABAN; TICLOPIDINE; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL PRACTICE; COMORBIDITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; HEART INFARCTION; HUMAN; KIDNEY DISEASE; KIDNEY INJURY; LIVER INJURY; NEPHROTOXICITY; PATIENT MONITORING; POSTMARKETING SURVEILLANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; TOXIC HEPATITIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; CARDIOVASCULAR DISEASE; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); KIDNEY; ORAL DRUG ADMINISTRATION; PATIENT SAFETY;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CARDIOVASCULAR DISEASES; CHEMICAL AND DRUG INDUCED LIVER INJURY; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY; KIDNEY DISEASES; PATIENT SAFETY;

EID: 84989172239     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.3529     Document Type: Review

References (71)

1. Riva N, Lip GY. A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long-term prevention of thromboembolic complications in patients with atrial fibrillation? Pol Arch Med Wewn. 2012; 122: 45-53.
2. Kornej J, Potpara T, Lip GY. Anticoagulation management in nonvalvular atrial fibrillation: current and future directions. Pol Arch Med Wewn. 2013; 123: 623-634.
3. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 17: 1467-1507.
4. Kovacs RJ, Flaker GC, Saxonhouse SJ, et al. Practical management of anticoagulation in patients with atrial fibrillation. J Am Coll Cardiol. 2015; 65: 1340-1360.
5. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149: 315-352.
6. Undas A, Pasierski T, Windyga J, et al. Practical aspects of new oral anticoagulant use in atrial fibrillation. Pol Arch Med Wewn. 2014; 124: 124-135.
7. Chan NC, Eikelboom JW, Weitz JI. Evolving treatments for arterial and venous thrombosis: role of the direct oral anticoagulants. Circ Res. 2016; 118: 1409-1424.
8. Hernandez I, Baik SH, Pinera A, et al. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015; 175: 18-24.
9. Romanelli RJ, Nolting L, Dolginsky M, et al. Dabigatran versus warfarin for atrial fibrillation in real-world clinical practice: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2016; 9: 126-134.
10. Raschi E, De Ponti F. Drug Utilization Research and Pharmacovigilance. In: Elseviers M, Wettermark B, Almarsdóttir AB, et al, eds. Drug Utilization Research: Methods and Applications. Chichester, UK: John Wiley & Sons, Ltd; 2016: 399-407.
11. Harpaz R, DuMouchel W, Shah NH, et al. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012; 91: 1010-1021.
12. McDonald CJ, Kalisch Ellett LM, Barratt JD, et al. A cross-country comparison of rivaroxaban spontaneous adverse event reports and concomitant medicine use with the potential to increase the risk of harm. Drug Saf. 2014; 37: 1029-1035.
13. McDonald CJ, Kalisch Ellett LM, Barratt JD, et al. An international comparison of spontaneous adverse event reports and potentially inappropriate medicine use associated with dabigatran. Pharmacoepidemiol Drug Saf. 2015; 24: 399-405.
14. Montastruc JL, Sommet A, Bagheri H, et al. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011; 72: 905-908.
15. Harpaz R, DuMouchel W, LePendu P, et al. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013; 93: 539-546.
16. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-1151.
17. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012; 172: 397-402.
18. Correia LC, Lopes AA. Dabigatran and myocardial infarction: meta-illusion? Arch Intern Med. 2012; 172: 823.
19. Douxfils J, Buckinx F, Mullier F, et al. Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and allcause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014; 3: e000515.
20. Clemens A, Fraessdorf M, Friedman J. Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vasc Health Risk Manag. 2013; 9: 599-615.
21. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003; 362: 1691-1698.
22. Lip GY, Lane DA. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med. 2010; 123: 785-789.
23. Lopes RD, Starr A, Pieper CF, et al. Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. Am J Med. 2010; 123: 134-140.
24. Tornyos A, Vorobcsuk A, Kupo P, et al. Apixaban and risk of myocardial infarction: meta-analysis of randomized controlled trials. J Thromb Thrombolysis. 2015; 40: 1-11.
25. Loke YK, Pradhan S, Yeong JK, et al. Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. Br J Clin Pharmacol. 2014; 78: 707-717.
26. Tornyos A, Kehl D, D'Ascenzo F, et al. Risk of myocardial infarction in patients with long-term non-Vitamin K antagonist oral anticoagulant treatment. Prog Cardiovasc Dis. 2016; 58: 483-494.
27. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366: 9-19.
28. Raschi E, Salvo F, Poluzzi E, et al. Safety meta-analysis: a call for appropriate use of disproportionality measures from spontaneous reporting systems. J Am Coll Cardiol. 2016; 67: 2193.
29. Fuhr U, Hellmich M. Channeling the flood of meta-analyses. Eur J Clin Pharmacol. 2015; 71: 645-647.
30. Stoto MA. Drug safety meta-analysis: promises and pitfalls. Drug Saf. 2015; 38: 233-243.
31. Caldeira D, Ferreira JJ, Pinto FJ, et al. Safety of non-Vitamin K antagonist oral anticoagulants - coronary risks. Expert Opin Drug Saf. 2016; 15: 731-740.
32. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015; 131: 157-164.
33. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med. 2014; 127: 650-656.
34. Lauffenburger JC, Farley JF, Gehi AK, et al. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc. 2015; 4
35. Sarges P, Steinberg JM, Lewis JH. Drug-induced liver injury: highlights from a review of the 2015 literature. Drug Saf. 2016;
36. Lewis JH. The art and science of diagnosing and managing drug-induced liver injury in 2015 and beyond. Clin Gastroenterol Hepatol. 2015; 13: 2173-2189.
37. Watkins PB, Desai M, Berkowitz SD, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 2011; 34: 243-252.
38. Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol. 2010; 407-418.
39. Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016; 14: 10.
40. Raschi E, De Ponti F. Drug- and herb-induced liver injury: progress, current challenges and emerging signals of post-marketing risk. World J Hepatol. 2015; 7: 1761-1771.
41. Lambert A, Cordeanu M, Gaertner S, et al. Rivaroxaban-induced liver injury: results from a venous thromboembolism registry. Int J Cardiol. 2015; 191: 265-266.
42. Cordeanu M, Lambert A, Gaertner S, et al. Apixaban-induced hepatotoxicity. Int J Cardiol. 2016; 204: 4-5.
43. Cordeanu M, Gaertner S, Bensalah N, et al. Rivaroxaban induced liver injury: a cholestatic pattern. Int J Cardiol. 2016; 216: 97-98.
44. Baig M, Wool KJ, Halanych JH, et al. Acute liver failure after initiation of rivaroxaban: a case report and review of the literature. N Am J Med Sci. 2015; 7: 407-410.
45. Aslan AN, Sari C, Bastug S, et al. Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban. Blood Coagul Fibrinolysis. 2016; 27: 226-227.
46. Liakoni E, Ratz Bravo AE, Terracciano L, et al. Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban. JAMA Intern Med. 2014;
47. Russmann S, Niedrig DF, Budmiger M, et al. Rivaroxaban postmarketing risk of liver injury. J Hepatol. 2014; 61: 293-300.
48. Liakoni E, Ratz Bravo AE, Krahenbuhl S. hepatotoxicity of new oral anticoagulants (NOACs). Drug Saf. 2015; 38: 711-720.
49. Raschi E, Poluzzi E, Koci A, et al. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol. 2015; 80: 285-293.
50. Fulcrand J, Lerooy A, Giraud J, et al. [Cytolysis in an elderly patient treated with dabigatran etexilate]. Therapie. 2013; 68: 332-334. French.
51. Rochwerg B, Xenodemetropoulos T, Crowther M, et al. Dabigatran-induced acute hepatitis. Clin Appl Thromb Hemost. 2012; 18: 549-550.
52. Caldeira D, Barra M, Santos AT, et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart. 2014; 100: 550-556.
53. Barrett P, Vuppalanchi R, Masuoka H, et al. Severe drug-induced skin and liver injury from rivaroxaban. Dig Dis Sci. 2015; 60: 1856-1858.
54. Chen M, Suzuki A, Borlak J, et al. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatol. 2015; 63: 503-514.
55. Kalgutkar AS, Dalvie D. Predicting toxicities of reactive metabolite-positive drug candidates. Annu Rev Pharmacol Toxicol. 2015; 55: 35-54.
56. Zhang D, He K, Raghavan N, et al. Comparative metabolism of 14Clabeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos. 2009; 37: 1738-1748.
57. Weinz C, Schwarz T, Kubitza D, et al. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos. 2009; 37: 1056-1064.
58. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008; 47: 285-295.
59. Anastasia EJ, Rosenstein RS, Bergsman JA, et al. Use of apixaban after development of suspected rivaroxaban-induced hepatic steatosis; a case report. Blood Coagul Fibrinolysis. 2015; 26: 699-702.
60. Chan KE, Giugliano RP, Patel MR, et al. NonVitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J Am Coll Cardiol. 2016; 67: 2888-2899.
61. Mlodawska E, Tomaszuk-Kazberuk A, Lopatowska P, et al. Management of patients with atrial fibrillation and chronic kidney disease in light of the latest guidelines. Pol Arch Med Wewn. 2016; 126: 353-362.
62. Stollberger C, Finsterer J. Pipe dreams about apixaban for stroke prevention in renal impairment. J Clin Pharmacol. 2016; 56: 646-647.
63. Wheeler DS, Giugliano RP, Rangaswami JR. Anticoagulation-related nephropathy. J Thromb Haemost. 2015;
64. Brodsky SV, Satoskar A, Chen J, et al. Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. Am J Kidney Dis. 2009; 54: 1121-1126.
65. Brodsky SV, Nadasdy T, Rovin BH, et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int. 2011; 80: 181-189.
66. Maddry JK, Amir MK, Sessions D, et al. Fatal dabigatran toxicity secondary to acute renal failure. Am J Emerg Med. 2013; 31: 462.
67. Ryan M, Ware K, Qamri Z, et al. Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats. Nephrol Dial Transplant. 2014; 29: 2228-2234.
68. Narasimha Krishna V, Warnock DG, Saxena N, et al. Oral anticoagulants and risk of nephropathy. Drug Saf. 2015; 38: 527-533.
69. Caldeira D, Goncalves N, Pinto FJ, et al. Risk of renal failure with the non-Vitamin K antagonist oral anticoagulants: systematic review and metaanalysis. Pharmacoepidemiol Drug Saf. 2015; 24: 757-764.
70. Shafi ST, Negrete H, Roy P, et al. A case of dabigatran-associated acute renal failure. WMJ. 2013; 112: 173-175.
71. Larsen TB, Skjoth F, Nielsen PB, et al. Comparative effectiveness and safety of non-Vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016; 353: i3189.